Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Christ

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Chemmedchem|April 3, 2020
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS<sup>G12C</sup>Jérémie Mortier, Anders Friberg, Volker Badock, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Zhonghui Lu, et al.
Bioorganic & Medicinal Chemistry Letters|February 1, 2008
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Rui-Qin Liu, et al.
Bioorganic & Medicinal Chemistry|September 1, 2000
The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonistP J Gilligan, C Baldauf, A Cocuzza, et al.
Journal of Medicinal Chemistry|May 28, 2004
Sultam hydroxamates as novel matrix metalloproteinase inhibitorsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Journal of Computer-Aided Molecular Design|December 26, 2016
Collaborating to improve the use of free-energy and other quantitative methods in drug discoveryBradley Sherborne, Veerabahu Shanmugasundaram, Alan C Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitorsJames J-W Duan, Lihua Chen, Zhonghui Lu, et al.
Journal of Medicinal Chemistry|November 1, 2002
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationshipsJames J-W Duan, Lihua Chen, Zelda R Wasserman, et al.
The Journal of Physical Chemistry. B|March 7, 2025
Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor BindingSukrit Singh, Vytautas Gapsys, Matteo Aldeghi, et al.
Toxicology and Applied Pharmacology|November 15, 2000
The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in ratsA E Mutlib, R J Gerson, P C Meunier, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Chemmedchem|April 3, 2020
Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS<sup>G12C</sup>Jérémie Mortier, Anders Friberg, Volker Badock, et al.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Zhonghui Lu, et al.
Bioorganic & Medicinal Chemistry Letters|February 1, 2008
Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)Gregory R Ott, Naoyuki Asakawa, Rui-Qin Liu, et al.
Bioorganic & Medicinal Chemistry|September 1, 2000
The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1 ,5-a]-pyrimidine: a corticotropin-releasing factor (hCRF1) antagonistP J Gilligan, C Baldauf, A Cocuzza, et al.
Journal of Medicinal Chemistry|May 28, 2004
Sultam hydroxamates as novel matrix metalloproteinase inhibitorsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Journal of Computer-Aided Molecular Design|December 26, 2016
Collaborating to improve the use of free-energy and other quantitative methods in drug discoveryBradley Sherborne, Veerabahu Shanmugasundaram, Alan C Cheng, et al.
Bioorganic & Medicinal Chemistry Letters|November 23, 2007
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitorsJames J-W Duan, Lihua Chen, Zhonghui Lu, et al.
Journal of Medicinal Chemistry|November 1, 2002
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationshipsJames J-W Duan, Lihua Chen, Zelda R Wasserman, et al.
The Journal of Physical Chemistry. B|March 7, 2025
Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor BindingSukrit Singh, Vytautas Gapsys, Matteo Aldeghi, et al.
Toxicology and Applied Pharmacology|November 15, 2000
The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in ratsA E Mutlib, R J Gerson, P C Meunier, et al.
Pageof 12